Skip to main content
. 2018 Oct 10;38(11):2111–2120. doi: 10.1007/s00296-018-4161-7

Fig. 2.

Fig. 2

Prescription prevalence of medications of interest within the first 3 years of RA disease. csDMARDs conventional synthetic disease-modifying antirheumatic drugs, bDMARDs biologic disease-modifying antirheumatic drugs, GCs glucocorticoids, NSAIDs non-steroidal anti-inflammatory drugs